1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
- 2022
-
Mark
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
(
- Contribution to journal › Article
- 2021
-
Mark
Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2019
-
Mark
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
(
- Contribution to journal › Article
-
Mark
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
(
- Contribution to journal › Article